100 research outputs found

    Velocities of Reacting Boron Particles within a Solid Fuel Ramjet Combustion Chamber

    Get PDF
    A 2D-laser doppler velocimeter was used to measure velocities of reacting boron (B) particles during the combustion of a metallised solid fuel slab inside a 20-combustion chamber. The solid fuel hydroxyl-terminated polybutadiene (HTPB) was enriched with B particles to increase its specific heat. To obtain information on the combustion process and on the movement of B particles, their velocities were measured. The experiments were performed at ambient pressure. The behaviour of the B particles concerning the exit velocities from the fuel slab has been discussed on the basis of the experimental results

    Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence

    Get PDF
    <p>Abstract</p> <p>Purpose</p> <p>To evaluate predictive factors for PSA bounce after <sup>125</sup>I permanent seed prostate brachytherapy and identify criteria that distinguish between benign bounces and biochemical relapses.</p> <p>Materials and methods</p> <p>Men treated with exclusive permanent <sup>125</sup>I seed brachytherapy from November 1999, with at least a 36 months follow-up were included. Bounce was defined as an increase ≄ 0.2 ng/ml above the nadir, followed by a spontaneous return to the nadir. Biochemical failure (BF) was defined using the criteria of the Phoenix conference: nadir +2 ng/ml.</p> <p>Results</p> <p>198 men were included. After a median follow-up of 63.9 months, 21 patients experienced a BF, and 35.9% had at least one bounce which occurred after a median period of 17 months after implantation (4-50). Bounce amplitude was 0.6 ng/ml (0.2-5.1), and duration was 13.6 months (4.0-44.9). In 12.5%, bounce magnitude exceeded the threshold defining BF. Age at the time of treatment and high PSA level assessed at 6 weeks were significantly correlated with bounce but not with BF. Bounce patients had a higher BF free survival than the others (100% versus 92%, p = 0,007). In case of PSA increase, PSA doubling time and velocity were not significantly different between bounce and BF patients. Bounces occurred significantly earlier than relapses and than nadir + 0.2 ng/ml in BF patients (17 vs 27.8 months, p < 0.0001).</p> <p>Conclusion</p> <p>High PSA value assessed 6 weeks after brachytherapy and young age were significantly associated to a higher risk of bounces but not to BF. Long delays between brachytherapy and PSA increase are more indicative of BF.</p
    • 

    corecore